Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lowered by HC Wainwright from $455.00 to $250.00 in a report published on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.
Several other brokerages also recently commented on ALNY. Zacks Research downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 23rd. BMO Capital Markets reissued an “outperform” rating and issued a $290.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, October 30th. Sanford C. Bernstein downgraded Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $376.00 to $199.00 in a report on Friday, October 30th. JPMorgan Chase & Co. dropped their price target on Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 30th. Finally, Bank of America reaffirmed a “buy” rating and set a $287.00 price target (down from $460.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eleven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $287.57.
Alnylam Pharmaceuticals Stock Down 1.1%
Shares of NASDAQ ALNY opened at $147.82 on Tuesday. The stock has a market cap of $19.80 billion, a P/E ratio of 7.67 and a beta of 0.42. The firm has a 50 day moving average price of $210.88 and a 200 day moving average price of $272.20. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.43 and a current ratio of 2.48. Alnylam Pharmaceuticals has a 52-week low of $146.51 and a 52-week high of $479.79.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, topping the consensus estimate of $1.66 by $14.60. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. During the same period last year, the business posted $2.90 earnings per share. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. Analysts expect that Alnylam Pharmaceuticals will post 6.85 EPS for the current year.
Insider Activity
In related news, EVP Bryan Supran sold 1,758 shares of the firm’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total transaction of $398,855.04. Following the sale, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Alnylam Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC raised its stake in shares of Alnylam Pharmaceuticals by 158.0% in the 3rd quarter. Kestra Advisory Services LLC now owns 6,994 shares of the biopharmaceutical company’s stock valued at $1,726,000 after purchasing an additional 4,283 shares during the period. Advisors Asset Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $1,054,000. Coastal Bridge Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 73.1% during the third quarter. Coastal Bridge Advisors LLC now owns 1,629 shares of the biopharmaceutical company’s stock worth $402,000 after buying an additional 688 shares during the period. Liontrust Investment Partners LLP boosted its position in shares of Alnylam Pharmaceuticals by 0.3% during the third quarter. Liontrust Investment Partners LLP now owns 26,834 shares of the biopharmaceutical company’s stock worth $6,621,000 after buying an additional 75 shares during the period. Finally, Kentucky Retirement Systems Insurance Trust Fund grew its holdings in shares of Alnylam Pharmaceuticals by 2.3% during the third quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 3,396 shares of the biopharmaceutical company’s stock worth $838,000 after buying an additional 75 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.
Alnylam Pharmaceuticals News Roundup
Here’s some of the latest news about ALNY:
- Neutral Sentiment: One article argues ALNY looks undervalued after a steep share decline. That view could attract value-oriented buyers, but it is an opinion and does not itself establish a near-term catalyst. Article: Alnylam (ALNY) Stock Looks Undervalued As Shares Fell 68%
- Negative Sentiment: Cantor Fitzgerald lowered its expectations for Alnylam, adding to concerns about the stock’s outlook. The available report does not specify the revised estimate or rationale. Article: Cantor Fitzgerald Has Lowered Expectations for Alnylam Pharmaceuticals Stock Price
- Negative Sentiment: Pomerantz LLP said it is investigating potential claims on behalf of Alnylam investors. An investigation is not a finding of wrongdoing, but the news may add legal and reputational uncertainty. Article: Pomerantz Law Firm Investigates Claims on Behalf of Alnylam Investors
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.
Further Reading
- Five stocks we like better than Alnylam Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
